Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II …
CJ Allegra, G Yothers, MJ O'Connell… - Journal of Clinical …, 2009 - ascopubs.org
Purpose The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed
to investigate the safety and effectiveness of adding bevacizumab to modified infusional …
to investigate the safety and effectiveness of adding bevacizumab to modified infusional …
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
CJ Allegra, G Yothers, MJ O'Connell, S Sharif… - Journal of clinical …, 2013 - ascopubs.org
Purpose The National Surgical Adjuvant Breast and Bowel Project trial C-08 was designed
to investigate the safety and efficacy of adding bevacizumab to fluorouracil, leucovorin, and …
to investigate the safety and efficacy of adding bevacizumab to fluorouracil, leucovorin, and …
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
CJ Allegra, G Yothers, MJ O'Connell… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed
to investigate the safety and efficacy of adding bevacizumab to modified FOLFOX6 …
to investigate the safety and efficacy of adding bevacizumab to modified FOLFOX6 …
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as …
A De Gramont, E Van Cutsem, J Tabernero… - Journal of Clinical …, 2011 - ascopubs.org
362 Background: Bevacizumab (BEV), a humanized anti-VEGF monoclonal antibody, has
demonstrated clinical efficacy in combination with 5-FU-based regimens in patients with …
demonstrated clinical efficacy in combination with 5-FU-based regimens in patients with …
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll… - The lancet …, 2012 - thelancet.com
Background Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in
metastatic colorectal cancer. Our aim was to assess the use of bevacizumab in combination …
metastatic colorectal cancer. Our aim was to assess the use of bevacizumab in combination …
Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
E Van Cutsem, D Lambrechts, H Prenen… - Journal of clinical …, 2011 - ascopubs.org
Molecularly targeted agents have improved the outcome of patients with metastatic
colorectal cancer (CRC) and other advanced malignant diseases. In fact, several phase III …
colorectal cancer (CRC) and other advanced malignant diseases. In fact, several phase III …
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
A De Gramont, C Boni, M Navarro… - Journal of Clinical …, 2007 - ascopubs.org
4007 Background: The MOSAIC study was designed to evaluate the effects of the FOLFOX4
regimen (5-FU/LV+ oxaliplatin) on 3-year disease free survival (DFS) probability in patients …
regimen (5-FU/LV+ oxaliplatin) on 3-year disease free survival (DFS) probability in patients …
Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years
A De Gramont, C Boni, M Navarro… - Journal of Clinical …, 2005 - ascopubs.org
3501 Background: MOSAIC trial was designed to demonstrate an increase in Disease Free
Survival (DFS) in stage II and III colon cancer. Methods: 2246 patients with completely …
Survival (DFS) in stage II and III colon cancer. Methods: 2246 patients with completely …
[HTML][HTML] Adjuvant therapy in colon cancer—what, when and how?
I Chau, D Cunningham - Annals of Oncology, 2006 - Elsevier
Bolus fluorouracil and leucovorin has been accepted as the standard adjuvant therapy in
stage III colon cancer for many years. New drugs such as irinotecan, oxaliplatin and oral …
stage III colon cancer for many years. New drugs such as irinotecan, oxaliplatin and oral …
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase …
Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon
cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper …
cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper …